Clinical Trial Update: The Efficacy and Safety of Cobitolimod (Kappaproct®) in Chronic Active Treatment Refractory Ulcerative Colitis Patients [Phase 3]

View source ↗

Summary

Phase 3 trial update on cobitolimod (Kappaproct) for chronic active treatment-refractory ulcerative colitis, with completed status and posted results in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ulcerative Colitis

Drugs mentioned

• Kappaproct (cobitolimod)

Snippet

Sponsor: InDex Pharmaceuticals | Conditions: Colitis, Ulcerative | Phase 3 | Status: COMPLETED | Results posted: 2018-01-24